10-QPeriod: Q1 FY2003

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2003

Filed April 30, 2003For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported robust financial performance for the first quarter ended March 31, 2003. The company experienced significant revenue growth, driven by both organic volume increases and contributions from strategic acquisitions, notably Unilab Corporation which closed in late February 2003. Net income saw a substantial increase compared to the prior year period, reflecting improved operational efficiencies stemming from Six Sigma and Standardization initiatives. Key financial metrics indicate strong operational execution. Despite some headwinds from severe weather and a local physician strike, the company managed to grow its top line and improve its bottom line. The acquisition of Unilab has significantly expanded its footprint, particularly in California, and while integration costs are anticipated, substantial annual synergies are projected. Investors should note the considerable increase in goodwill on the balance sheet due to acquisitions, alongside increased debt to finance these strategic moves. Overall, Quest Diagnostics demonstrated strong operating momentum and strategic progress in the quarter.

Key Highlights

  • 1Net revenues increased by 15.4% year-over-year to $1.09 billion, including one month of Unilab's results.
  • 2Net income rose significantly to $88.0 million ($0.86 per diluted share) from $66.7 million ($0.67 per diluted share) in the prior year period.
  • 3Acquisition of Unilab Corporation completed on February 28, 2003, for $697 million (cash and stock), significantly increasing goodwill.
  • 4Testing volume (requisitions) grew by 11.9% year-over-year, aided by acquisitions, though impacted by weather and a physician strike.
  • 5Average revenue per requisition increased by 3.6%, driven by a shift to higher-value tests and a favorable payer mix.
  • 6Selling, general, and administrative expenses as a percentage of net revenues improved to 25.5% from 27.3% due to efficiencies.
  • 7Company took on new debt, with $450 million in borrowings under a term loan facility to finance the Unilab acquisition and debt repayment.

Frequently Asked Questions

Revenue growth was primarily driven by a combination of organic testing volume increases and the impact of recent acquisitions, notably the one-month contribution from Unilab Corporation which closed on February 28, 2003. Pro forma revenue growth, assuming Unilab was acquired earlier, was 3.2%.

The acquisition of Unilab significantly increased Quest Diagnostics' assets, particularly goodwill which rose by approximately $730 million on a preliminary basis. It also led to a substantial increase in long-term debt as the company financed the acquisition with a new $450 million term loan facility and repaid Unilab's existing debt. The acquisition also added approximately $187 million in current assets and $54 million in current liabilities.

Quest Diagnostics estimates it will incur up to $20 million in integration costs, primarily for severance and facility consolidation, expected through the first half of 2005. The company anticipates realizing $25 million to $30 million in annual synergies by the end of 2005.

Net income increased to $88.0 million from $66.7 million in the prior year's first quarter, resulting in diluted EPS of $0.86 compared to $0.67. This improvement was attributed to revenue growth and operational efficiencies from Six Sigma and Standardization initiatives, partially offsetting increased compensation costs and IT investments.